infecti
caus
respiratori
diseas
common
dog
canin
distemp
viru
adenoviru
parainfluenza
influenza
herpesviru
pneumoviru
respiratori
coronaviru
bordetella
bronchiseptica
variou
mycoplasma
spp
streptococcu
equi
var
zooepidemicu
document
molecular
diagnost
assay
detect
viral
bacteri
pathogen
avail
agent
unit
state
modifi
live
vaccin
mlvx
intranas
administr
current
avail
adenoviru
b
bronchiseptica
parainfluenza
vaccin
induc
steril
immun
vaccin
dog
still
develop
clinic
sign
diseas
expos
virul
strain
current
unknown
administr
mlvx
agent
result
posit
molecular
diagnost
assay
result
dog
without
previou
vaccin
transient
posit
molecular
diagnost
assay
result
common
vaccin
posit
predict
valu
diagnost
assay
predict
diseas
caus
agent
dog
would
decreas
purpos
studi
determin
impact
administr
singl
dose
commerci
avail
mlvx
adenoviru
b
bronchiseptica
parainfluenza
contain
includ
part
facil
standard
initi
vaccin
seri
parenter
administr
mlvx
contain
adenoviru
canin
distemp
viru
parvoviru
result
commerci
avail
polymeras
chain
reaction
pcr
panel
amplifi
rna
dna
studi
complet
institut
anim
care
use
approv
beagl
puppi
hous
commerci
breed
facil
puppi
hous
close
facil
without
contact
dog
staff
member
follow
facil
barrier
precaut
cours
studi
steril
cotton
swab
gentli
rub
entranc
extern
nare
second
swab
gentli
rub
mucosa
oropharynx
nonsed
puppi
swab
store
separ
steril
plastic
tube
store
ship
overnight
express
cold
pack
perform
molecular
total
puppi
screen
twice
describ
week
apart
neg
nucleic
acid
target
organ
eight
puppi
randomli
select
studi
hous
separ
room
breed
facil
durat
studi
puppi
approxim
week
age
sampl
collect
day
sq
administr
mlvx
contain
adenoviru
canin
distemp
viru
administr
contain
adenoviru
b
bronchiseptica
parainfluenza
follow
manufactur
instruct
approxim
ml
per
nare
nasal
pharyng
swab
collect
day
molecular
sneez
cough
associ
mlvx
administr
note
cours
studi
advers
effect
associ
collect
nasal
oropharyng
swab
note
time
studi
perform
pcr
panel
util
also
includ
primer
canin
distemp
viru
rna
none
sampl
collect
cours
studi
posit
contrast
nucleic
acid
adenoviru
b
bronchiseptica
parainfluenza
amplifi
sampl
site
puppi
multipl
day
vaccin
administr
tabl
adenoviru
administ
vaccin
type
sourc
viru
determin
increas
number
posit
sampl
vaccin
suggest
local
replic
vaccin
strain
decreas
number
posit
sampl
time
suggest
immun
respons
inhibit
organ
replic
howev
quantit
pcr
assay
normal
total
dnarna
swab
would
need
confirm
deni
hypothes
pcr
laboratori
adher
standard
oper
procedur
includ
use
posit
neg
control
thu
erron
result
unlik
agent
consid
common
kennel
cough
syndrom
includ
canin
distemp
viru
adenoviru
parainfluenza
b
bronchiseptica
howev
emerg
pathogen
includ
influenza
herpesviru
respiratori
coronaviru
pantrop
coronaviru
pneumoviru
agent
well
equi
var
zooepidemicu
mycoplasma
spp
identifi
caus
canin
infecti
respiratori
diseas
determin
agent
import
target
treatment
particularli
dog
fail
respond
standard
treatment
anim
shelter
environ
agent
identif
critic
outbreak
control
individu
case
bacteri
viral
shed
postvaccin
administr
complic
diagnost
test
treatment
especi
problemat
shelter
environ
dog
routin
vaccin
intak
viral
shed
vaccin
detect
vaccin
strain
b
bronchiseptica
detect
via
nasal
cultur
week
vaccin
commerci
avail
respiratori
pcr
panel
rel
cost
time
effect
diagnost
method
identifi
multipl
respiratori
pathogen
howev
amplif
nucleic
acid
may
inher
lead
inaccur
clinic
diagnosi
small
amount
amplifi
anim
even
though
agent
may
present
suffici
quantiti
caus
diseas
studi
nucleic
acid
organ
contain
vaccin
amplifi
site
multipl
day
via
pcr
although
clinic
sign
respiratori
diseas
observ
thu
interpret
pcr
panel
result
diagnos
includ
consider
recent
vaccin
statu
clinic
sign
diseas
use
quantit
pcr
sequenc
differ
may
abl
differenti
vaccin
pathogen
agent
shed
may
use
diagnost
futur
revers
transcriptas
pcr
use
amplifi
canin
distemp
viru
rna
blood
urin
conjunctiv
swab
administr
sq
studi
pcr
panel
amplifi
distemp
viru
rna
nasal
pharyng
swab
studi
need
determin
whether
neg
result
strain
vaccin
viru
reach
nasal
pharyng
tissu
present
level
detect
limit
assay
use
